Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ility and edema and prevent the inappropriate growth of new blood vessels in the retina in patients with CRVO.

About VEGF Trap-Eye

VEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  VEGF Trap-Eye is a specific and highly potent blocker of these growth factors.  VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Bayer HealthCare and Regeneron are collaborating on the global development of VEGF Trap-Eye for the treatment of the neovascular form of age related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011. Bayer plans to file regulatory submissions in Europe in the second quarter of 2011.

In April 2011, Bayer HealthCare and Regeneron announced the initiation of a Phase 3 program in DME.

Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the companies will share equally the profits from any future sales of VEGF Trap-Eye.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, disease
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Foundation Radiology Group (FRG), the region,s premier provider ... it has been named the Hospital Council of Western ... Pittsburgh-based radiology practice that brings the expertise of a ... across Pennsylvania and the tri-state area. By partnering with ...
... Oct. 18 Fenwal, Inc., a global medical ... safety and availability, announced today it has signed ... sell, market and distribute the AccuVein AV300 vein ... North America. (Photo:   http://photos.prnewswire.com/prnh/20101018/CG83159 ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 3
(Date:7/28/2014)... 28, 2014 TherapySites, the ... professionals, announced today its affiliation with the Illinois ... new relationship allows TherapySites to continue to extend their ... and promotional offers. , “There has been a fundamental ... With nearly 3 billion Internet users, it is ...
(Date:7/28/2014)... Footwear etc. is delighted to showcase ... With shoes, sandals, and boots that have only increased ... handmade comfort shoes and quality that is ... to rely on the superb value, durability, and high-end ... sandals contain the highest quality materials available, and as ...
(Date:7/28/2014)... San Antonio, TX (PRWEB) July 28, 2014 ... July 28, the Editorial Board of Living with ... that focuses on disabling digestive disorders that include hepatitis, ... malnutrition. , The important new article highlights ... Disability award, those afflicted with hepatitis and other disabling ...
(Date:7/28/2014)... 2014 According to the Drama Method Pdf ... guide that helps women easily get the attention of the ... reveals in its review that this book can teach ladies ... man. The book also instructs them how to conquer a ... its Drama Method review that this book is divided into ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... in Sweden shows that phthalates from PVC flooring materials is ... cause asthma and allergies, as well as other chronic diseases ... softening agents with food but also by breathing and through ... that occur in construction materials and a great number of ...
... , TUESDAY, May 22 (HealthDay News) -- Patients undergoing ... threading a camera through the colon to detect precancerous ... found that patients overwhelmingly preferred colonoscopy to the less ... Colonoscopy has long been the standard of care for ...
... inhaled corticosteroids in patients with respiratory disorders who develop ... incidence and severity of parapneumonic effusion, according to a ... effusion is a type of pleural effusion (excess fluid ... space that surrounds the lungs) that arises as a ...
... researchers will present findings on prostate cancer risk, screening, ... of the American Urological Association May 19-23 in Atlanta. ... expert comment for reporters covering the conference. Mayo ... dates include: No negative impact on overall ...
... (RCTs) are critical for determining effectiveness of medical therapies, ... these studies compared with other western countries, states an ... Journal ). Dr. Salim Yusuf, McMaster University and ... University of British Columbia, argue in the analysis and ...
... Ky. (May 17, 2012) The University of Kentucky Markey ... a deadly blood and bone marrow disease often caused by ... Edward P. Evans Foundation, along with a $1.25 million donor ... Evans Foundation grant will fund five research labs over five ...
Cached Medicine News:Health News:Phthalates in PVC floors taken up by the body in infants 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
... Stent may become a practice-changing technology for ... treatment of lower urinary tract symptoms (LUTS). ... retention , Men unfit for surgery , ... therapy - TUMT, TUNA, Brachytherapy, Cryotherapy , ...
Medicine Products: